Teva Pharmaceutical Industries Limited
TEVA
$18.46
-$0.34-1.81%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.63B | 16.62B | 16.54B | 16.77B | 16.29B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.63B | 16.62B | 16.54B | 16.77B | 16.29B |
| Cost of Revenue | 8.38B | 8.45B | 8.48B | 8.41B | 8.23B |
| Gross Profit | 8.25B | 8.17B | 8.06B | 8.36B | 8.06B |
| SG&A Expenses | 3.75B | 3.73B | 3.70B | 3.65B | 3.57B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 16.00M | 10.00M | -9.00M | -1.00M | 11.00M |
| Total Operating Expenses | 13.13B | 13.19B | 13.17B | 13.04B | 12.80B |
| Operating Income | 3.50B | 3.42B | 3.37B | 3.73B | 3.49B |
| Income Before Tax | -70.00M | -519.00M | -1.28B | -529.00M | -143.00M |
| Income Tax Expenses | 93.00M | 801.00M | 675.00M | 688.00M | 607.00M |
| Earnings from Continuing Operations | -163.00 | -1.32K | -1.96K | -1.22K | -750.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00M | 34.00M | 320.00M | 258.00M | 297.00M |
| Net Income | -158.00M | -1.29B | -1.64B | -959.00M | -453.00M |
| EBIT | 3.50B | 3.42B | 3.37B | 3.73B | 3.49B |
| EBITDA | 4.52B | 4.45B | 4.43B | 4.79B | 4.57B |
| EPS Basic | -0.14 | -1.14 | -1.45 | -0.84 | -0.40 |
| Normalized Basic EPS | 1.40 | 1.39 | 1.61 | 1.74 | 1.64 |
| EPS Diluted | -0.16 | -1.15 | -1.46 | -0.86 | -0.41 |
| Normalized Diluted EPS | 1.39 | 1.38 | 1.61 | 1.73 | 1.63 |
| Average Basic Shares Outstanding | 4.55B | 4.54B | 4.52B | 4.51B | 4.50B |
| Average Diluted Shares Outstanding | 4.59B | 4.56B | 4.52B | 4.53B | 4.53B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |